EU Finalizes GMP Rules, Inspection Procedures For Investigational And Finished Drugs
Executive Summary
Two new legal acts have been adopted by the European Commission specifying updated good manufacturing practice requirements for investigational medicinal products and finished medicines. The legislation take into account recent updates to the EU rules on the safety of medicines.
You may also be interested in...
EMA Consults On Two-Step Process For Release And Shipping Of Investigational Products
The European Medicines Agency has issued a draft guideline to support the upcoming Clinical Trials Regulation, explaining how investigational medicinal products should be handled before they are sent to clinical trial sites.
EU Issues GMP Guide For Investigational Drugs Under Clinical Trials Regulation
A new EU guideline explains how manufacturers and importers of investigational medicinal products can comply with the provisions of a 2017 delegated regulation specifying good manufacturing practice requirements and inspection procedures for such products.
Commission Delays EU GMP Guide For Advanced Therapies To Address Inspectorates’ Concerns
The finalization of the EU GMP guideline for advanced therapy medicinal products has been pushed back as the European Commission is trying to address concerns raised by a group representing the world's leading pharmaceutical inspectorates. While the industry is disappointed with the delay, it supports the Commission’s efforts to secure consensus on this key guideline.